The launch of Lyprinol in SA, now offers a natural therapy to help reduce chronic pain in people suffering from osteoarthritis, rheumatoid arthritis and asthma. It has been shown to be more effective than certain non-steroidal anti-inflammatory drugs (NSAIDs) while exhibiting none of the side-effects normally experienced during NSAID treatment. One study undertaken at the University of Queensland showed that Lyprinol outperformed Indomethacin & Ibuprofen by 2:1. Subsequent trials showed that Lyprinol was 175 times more potent than evening primrose and salmon oil and that it was 200 times more effective than flax oil in controlling arthritic joint swelling. Lyprinol is a natural marine extract from the oil of the New Zealand green-lipped mussel (Perna canaliculus) and is the most studied natural alternative known to provide relief from inflammatory pain and asthmatic symptoms.

Even people who are allergic to seafood and shellfish can safely use Lyprinol as it contains no protein. It is a rare combination of five lipid groups, including omega 3 polyunsaturated fatty acids (PUFAs), which are vital in maintaining health. More specifically, it is rich in the omega 3s, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are known to be potent anti-inflammatory agents. What makes Lyprinol unique, is that it contains two additional PUFAs, namely ETA and OTA that are not found in fish oils. These omega 3 PUFAs play an important role in blocking the production of pro-inflammatory enzymes such as 5-lipoxygenase (5-LOX) that synthesize leukotrienes, which cause inflammatory diseases such as osteoarthritis and rheumatoid arthritis which are associated with chronic pain caused by inflammation of the joints. Lyprinol helps to reduce this type of chronic pain. The majority of studies showed a reduction in joint tenderness, pain and morning stiffness and improved grip ability.

Lyprinol also helps asthmatics as it inhibits the formation of broncho-constricting leukotrienes. These leukotrienes are partly responsible for the production of excessive mucous and the constriction of the bronchial airways. A study conducted at the Pavlov Medical University Hospital in St Petersburg, found the following results after only 56 days. There was a 50% reduction in rescue medicine, a 65% reduction in exhaled H2O2 (hydrogen peroxide), a significant reduction in chest tightness and the incidence of night-time attacks. They concluded that Lyprinol was an effective means of treating inflammation in the airways. All three of these conditions can be debilitating and reduce the quality of your life. Note, that in all the above conditions individual results may vary.